Status:
UNKNOWN
Optimisation of Radiotherapy in Rectal Cancer (ORREC)
Lead Sponsor:
University of Manchester
Collaborating Sponsors:
The Christie NHS Foundation Trust
Conditions:
Rectal Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective study using images acquired routinely for diagnosis of rectal cancer to see if these could be used to predict responses to radiotherapy treatment and if it can, whether the tre...
Detailed Description
The treatment of locally advanced rectal cancer is primarily radiotherapy (+/- chemotherapy) followed by surgery. The reason for radiotherapy is to reduce the risk of recurrence after surgery or to sh...
Eligibility Criteria
Inclusion
- Histologically confirmed rectal adenocarcinoma.
- Received pelvic radiotherapy (+/- chemotherapy) as neo-adjuvant treatment
- Age 18 and above
Exclusion
- Other rectal pathologies.
- Patients less than 18yrs at diagnosis.
Key Trial Info
Start Date :
September 23 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2021
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04090450
Start Date
September 23 2019
End Date
March 31 2021
Last Update
September 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Christie Hospital NHS Foundation Trust
Manchester, England, United Kingdom, M20 4BX